# US 8,652,485 B2 · Peptide for vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,652,485 B2
- Document ID: US8652485B2
- Status: Granted
- Kind: B2
- Application number: 12/673,412
- Filed: 2008-08-15
- Published: 2010-10-14
- Granted: 2014-02-18
- Earliest claimed: 2007-08-15
- Assignees: Circassia Limited
- Applicants: Roderick Peter Hafner; Paul Laidler; Mark Larche
- Inventors: Roderick Peter Hafner; Paul Laidler; Mark Larche
- Web page: https://patentgrep.com/patent/US8652485B2

## CPC

- A61K 39/0003: {Invertebrate antigens}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/35: Allergens
- A61K 39/36: from pollen
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/06: Antianaemics
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 33/14: Ectoparasiticides, e.g. scabicides
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/415: from plants
- C07K 14/435: from animals; from humans
- C07K 14/43531: {from mites}
- C07K 16/16: against material from plants
- C07K 16/18: against material from animals or humans
- G01N 33/56977: {HLA or MHC typing}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/0002: {Fungal antigens, e.g. Trichophyton, Aspergillus, Candida}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.

## Claims

### Claim 1

A composition comprising at least four polypeptides selected from the following group:
(a) the polypeptide consisting of the sequence DLRQMRTVTPIRMQGGSGS (HDM203B, SEQ ID NO: 83);
(b) the polypeptide consisting of the sequence ESVKYVQSNGGAI (HDM201; SEQ ID NO: 80);
(c) the polypeptide consisting of the sequence SYYRYVAREQS (HDM205, SEQ ID NO: 85);
(d) the polypeptide consisting of the sequence NYSQIYPPNVNKIREA (HDM101A, SEQ ID NO: 73); and
(e) the polypeptide consisting of the sequence ELVDSASQHG (SEQ ID NO: 101).

### Claim 2 (depends on 1)

The composition of claim 1, wherein each polypeptide has a concentration in the range of 0.03 to 200 nmol/ml, 0.3 to 200 nmol/ml or 30 to 120 nmol/ml.

### Claim 3 (depends on 1)

The composition of claim 1, formulated for oral administration, nasal administration, epicutaneous administration, subcutaneous administration, sublingual administration, intradermal administration, buccal administration or for administration by inhalation or by injection.